mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80–96 years at 2 weeks after the second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titers in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher, respectively, after dual vaccination. Post-vaccine sera mediated strong neutralization of live Victoria infection and although neutralization titers were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“It is likely that these findings underlie the excellent clinical protection that is emerging from vaccine trials in this population with 94 % protection from symptomatic infection in a real- world setting and 89 % efficacy in people over 80 years of age (Dagan et al., 2021; Bernal et al., 2021).”
BackgroundBernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · doi:10.1101/2021.03.01.21252652 · Cited by 1,389
Self-citationMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758 · cited 2×
“1 VOC contains a range of mutations within the spike domain including E484K which can mediate escape from recognition by some antibodies (Sabino et al., 2021).”
BackgroundAntibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
B-cell responses to vaccination at the extremes of age
Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Self-citationAbu Jabal, K., Ben-Amram, H., Beiruti, K., Batheesh, Y., Sussan, C., Zarka, S., & Edelstein, M. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.6.2100096 · Cited by 271
Krammer, F., Srivastava, K., the PARIS team, & Simon, V. (2021) · doi:10.1101/2021.01.29.21250653 · Cited by 116
Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults
Cox, L. S., Bellantuono, I., Lord, J. M., Sapey, E., Mannick, J. B., Partridge, L., Gordon, A. L., Steves, C. J., & Witham, M. D. (2020) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30011-8 · Cited by 73 · cited 1×
“However, in order for this to be achieved, it will be essential that vaccine- induced immune responses are elicited effectively in people of older age (Cox et al., 2020).”
Background
Research works printed but not linked: 10
- Chen, 2021, Resistance of SARS-COV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, Nature Medicine, 27, 717, 10.1038/s41591-021-01294-w · DOI · Paper page
- Cook, 2020, Validation of a Combined Elisa to Detect Igg, Iga and IGM Antibody Responses to SARS-COV-2 in Mild or Moderate Non-Hospitalised Patients, 10.1101/2020.11.30.20229732 · doi:10.1101/2020.11.30.20229732
- Egorov, 2018, The changing landscape of naive T cell receptor repertoire with human aging, Frontiers in Immunology, 9, 10.3389/fimmu.2018.01618 · DOI · Paper page
- Krutikov, 2021, Incidence of SARS-CoV-2 Infection According to Baseline Antibody Status in Staff and Residents of 100 Long Term Care Facilities (VIVALDI Study, 10.1101/2021.03.08.21253110 · DOI
- Levi, 2021, A Cautionary Note on Recall Vaccination in Ex-COVID-19 Subjects, 10.1101/2021.02.01.21250923 · DOI
- Manisty, 2021, Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection, EBioMedicine, 65, 10.1016/j.ebiom.2021.103259 · DOI
- Morley, 2020, Sensitive Detection of SARS-CoV-2–Specific Antibodies in Dried Blood Spot Samples, Emerging Infectious Disease Journal, 26, 10.3201/eid2612.203309 · DOI
- Pietrobon, 2020, I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People, Frontiers in Immunology, 11, 10.3389/fimmu.2020.579220 · DOI · Paper page
- Salvagno, 2021, Anti-sars-cov-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mrna bnt162b2 vaccination, Diagnostics, 11, 10.3390/diagnostics11050832 · DOI
- Zuo, 2021, Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection, Nature Immunology, 22, 10.1038/s41590-021-00957-7 · doi:10.1038/s41590-021-00957-7
Cited by
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Self-citationSpike-antibody waning after second dose of BNT162b2 or ChAdOx1
Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01642-1 · Cited by 393
Covid‐19 vaccines and variants of concern: A review
Hadj Hassine, I. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2313 · Cited by 383
Wei, J., Stoesser, N., Matthews, P. C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00947-3 · Cited by 331
Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elrefaey, A. M. E., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01163-3 · Cited by 85
“Another interpretation is that the low neutralizing antibody titres we and others have seen in older adult vaccinees 1,33 may contribute disproportionately to the lack of neutralization of antigenically distinct SARS-CoV-2 variants.”
Self-citation
Metadata
- Authors
- Parry, H., Tut, G., Bruton, R., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D'Arcangelo, S., Hallis, B., Makin, A., Richter, A., Zuo, J., & Moss, P.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-09-29
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3203293048
- Cited by
- 36
- References
- 12
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (am)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- National Core Studies (Immunity programme)
- UK Coronavirus Immunology Consortium (UKRI/DHSC)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.